Axomadol

Drug Profile

Axomadol

Alternative Names: EN3324; GRT0151Y

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Grunenthal
  • Class Analgesics; Cyclohexanes; Phenyl ethers
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pain; Postoperative pain
  • Discontinued Neuropathic pain

Most Recent Events

  • 14 Aug 2015 Phase-II development for Pain is ongoing in Europe
  • 26 Mar 2012 Axomadol is still in phase IIb development for chronic Pain & chronic Neuropathic pain
  • 17 Aug 2011 Axomadol is no longer licensed to Endo Pharmaceuticals in the US and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top